
  
    
      
        DESCRIPTION_NNP of_IN CASE_NN
        A_DT 31_CD -_: year-old_JJ white_JJ male_NN with_IN no_DT significant_JJ past_JJ medical_JJ history_NN is_VBZ referred_VBN by_IN his_PRP$
        workplace_NN to_TO a_DT primary_JJ care_NN physician_NN for_IN an_DT elevated_VBD blood_NN pressure_NN (_( BP_NNP )_) ._. He_PRP presents_VBZ to_TO
        the_DT clinic_NN with_IN no_DT complaints_NNS ._. His_PRP$ mother_NN and_CC grandmother_NN both_DT have_VBP diabetes_NN ,_, and_CC his_PRP$
        father_NN has_VBZ hypertension_NN ._. He_PRP has_VBZ had_VBD a_DT 15_CD -_: pound_NN (_( lb_NN )_) weight_NN gain_NN over_IN the_DT last_JJ year_NN and_CC has_VBZ
        become_VBN more_RBR sedentary_JJ ._.
        His_PRP$ BP_NNP is_VBZ 142_CD /_NN 90_CD mm_NN Hg_NNP ,_, pulse_NN is_VBZ 88_CD beats_VBZ per_IN minute_NN (_( bpm_NN )_) ,_, weight_NN is_VBZ 209_CD lb_NN ,_, and_CC height_NN
        is_VBZ 5_CD ′_NN 11_CD ″_NN ._. On_IN examination_NN he_PRP displays_VBZ moderate_JJ central_JJ obesity_NN ,_, but_CC otherwise_RB the_DT
        examination_NN is_VBZ normal_JJ ._. His_PRP$ fasting_VBG cholesterol_NN is_VBZ 228_CD mg_NN /_NN dl_NN (_( to_TO convert_VB milligrams_NNS per_IN
        deciliter_NN of_IN cholesterol_NN [_NN total_JJ ,_, HDL_NNP or_CC LDL_NNP ]_NN to_TO micromoles_NNS per_IN liter_NN ,_, divide_VBP by_IN 39_CD )_) ,_,
        low-density_NN lipoprotein_NN (_( LDL_NNP )_) is_VBZ 166_CD mg_NN /_NN dl_NN ,_, high-density_JJ lipoprotein_NN (_( HDL_NNP )_) is_VBZ 32_CD mg_NN /_NN dl_NN ,_,
        triglycerides_NNS (_( TG_NNP )_) are_VBP 223_CD mg_NN /_NN dl_NN (_( to_TO convert_VB mg_NN /_NN dl_NN of_IN triglycerides_NNS to_TO mmol_NN /_NN l_NN ,_, divide_VBP by_IN
        89_CD )_) ,_, and_CC fasting_VBG glucose_NN is_VBZ 114_CD mg_NN /_NN dl_NN (_( to_TO convert_VB mg_NN /_NN dl_NN of_IN glucose_NN to_TO mmol_NN /_NN l_NN ,_, divide_VBP by_IN
        18_CD )_) ._.
        
          What_WP Is_VBZ the_DT diagnosis_NN ?_.
          This_DT patient_NN meets_VBZ the_DT diagnostic_JJ criteria_NNS for_IN the_DT metabolic_JJ syndrome_NN as_IN defined_VBN by_IN
          the_DT National_NNP Cholesterol_NNP Education_NNP Program_NNP Adult_NNP Treatment_NNP Panel_NNP III_NNP guidelines_NNS [_NN 1_CD ]_NN ._. Any_DT
          three_CD or_CC more_JJR of_IN the_DT criteria_NNS make_VBP this_DT diagnosis_NN (_( see_VB Table_NNP 1_LS )_) ._. Intensive_NNP lifestyle_NN
          modifications_NNS such_JJ as_IN exercise_NN and_CC weight_NN loss_NN should_MD be_VB made_VBN to_TO improve_VB cholesterol_NN ,_,
          blood_NN pressure_NN ,_, and_CC other_JJ cardiovascular_JJ disease_NN (_( CVD_NNP )_) risk_NN factors_NNS [_NN 2_CD ]_NN ._. It_PRP may_MD be_VB timely_JJ
          to_TO address_VB the_DT prevention_NN of_IN diabetes_NN in_IN patients_NNS with_IN metabolic_JJ syndrome_NN since_IN these_DT
          patients_NNS are_VBP at_IN high_JJ risk_NN for_IN development_NN of_IN type_NN 2_CD diabetes_NN ._. Lifestyle_NNP changes_NNS delay_VBP the_DT
          onset_NN or_CC prevent_VB the_DT incidence_NN of_IN type_NN 2_CD diabetes_NN in_IN patients_NNS with_IN glucose_NN intolerance_NN ,_, a_DT
          key_JJ feature_NN of_IN metabolic_JJ syndrome_NN [_NN 3_CD ]_NN ._. The_DT patient_NN is_VBZ started_VBN on_IN an_DT exercise_NN and_CC weight_NN
          loss_NN program_NN ,_, sent_VBD for_IN nutritional_JJ counseling_NN ,_, and_CC scheduled_VBD for_IN a_DT return_NN clinic_NN
          appointment_NN for_IN three_CD months_NNS later_RB ._.
        
        
          Two_CD Years_NNS Later_RB
          The_DT patient_NN returns_NNS to_TO the_DT clinic_NN two_CD years_NNS later_RB ._. He_PRP presents_VBZ with_IN complaints_NNS of_IN
          increasing_VBG frequency_NN of_IN urination_NN and_CC episodes_NNS of_IN blurry_JJ vision_NN ._. He_PRP has_VBZ nocturia_NN and_CC has_VBZ
          lost_VBN 5_CD lb_NN in_IN the_DT last_JJ week_NN ._. Otherwise_RB ,_, his_PRP$ review_NN of_IN systems_NNS is_VBZ unremarkable_JJ ._. His_PRP$ blood_NN
          pressure_NN is_VBZ 146_CD /_NN 88_CD mm_NN Hg_NNP ,_, pulse_NN 80_CD bpm_NN ,_, and_CC weight_NN 216_CD lb_NN ._. His_PRP$ fundoscopic_JJ examination_NN is_VBZ
          normal_JJ ._. He_PRP continues_VBZ to_TO have_VB moderate_JJ central_JJ obesity_NN ._. Current_JJ medications_NNS are_VBP a_DT thiazide_NN
          diuretic_JJ ,_, 12_CD ._. 5_LS mg_NN once_RB daily_JJ (_( QD_NNP )_) ,_, started_VBD one_CD year_NN prior_RB ._. A_DT non-fasting_JJ blood_NN sugar_NN is_VBZ
          267_CD mg_NN /_NN dl_NN ._.
          
            Can_MD a_DT diagnosis_NN be_VB made_VBN ?_.
            There_EX are_VBP three_CD criteria_NNS for_IN the_DT diagnosis_NN of_IN type_NN 2_CD diabetes_NN as_IN defined_VBN by_IN the_DT
            American_NNP Diabetes_NNP Association_NNP (_( ADA_NNP )_) ,_, of_IN which_WDT any_DT one_CD is_VBZ sufficient_JJ to_TO make_VB the_DT
            diagnosis_NN (_( see_VB Box_NNP 1_LS )_) ._. This_DT patient_NN meets_VBZ the_DT criteria_NNS for_IN type_NN 2_CD diabetes_NN ._. He_PRP does_VBZ not_RB
            need_VB to_TO have_VB a_DT fasting_VBG blood_NN sugar_NN done_VBN because_IN a_DT random_JJ glucose_NN greater_JJR than_IN 200_CD mg_NN /_NN dl_NN
            with_IN symptoms_NNS of_IN diabetes_NN meets_VBZ the_DT first_JJ criterion_NN ._. Failing_NNP to_TO comply_VB with_IN lifestyle_NN
            modification_NN ,_, his_PRP$ weight_NN has_VBZ increased_VBD 7_CD lb_NN in_IN two_CD years_NNS and_CC likely_JJ contributes_VBZ to_TO his_PRP$
            development_NN of_IN diabetes_NN ._. Of_IN note_NN ,_, his_PRP$ recent_JJ weight_NN loss_NN is_VBZ presumably_RB due_JJ to_TO overt_JJ
            hyperglycemia_NN and_CC glycosuria_NN ,_, further_JJ underestimating_VBG his_PRP$ true_JJ weight_NN increase_NN ._.
            His_PRP$ additional_JJ investigations_NNS are_VBP as_IN follows_VBZ :_: fasting_VBG glucose_NN ,_, 215_CD mg_NN /_NN dl_NN ;_: hemoglobin_NN
            A_DT 1_CD c_SYM (_( HbA_NNP
            1_CD c_SYM )_) ,_, 8_CD ._. 6_CD %_NN ;_: and_CC urine_NN albumin-to-creatinine_JJ ratio_NN ,_, 2_CD ._. 0_CD mg_NN /_NN mmol_NN
            (_( normal_JJ is_VBZ <_NN 2_CD ._. 5_LS mg_NN /_NN mmol_NN in_IN men_NNS and_CC <_NN 3_CD ._. 5_LS mg_NN /_NN mmol_NN in_IN women_NNS )_) ._. LDL_NNP is_VBZ 176_CD mg_NN /_NN dl_NN ,_, HDL_NNP
            32_CD mg_NN /_NN dl_NN ,_, and_CC TG_NNP 292_CD mg_NN /_NN dl_NN ._. His_PRP$ electrocardiogram_NN is_VBZ normal_JJ ._.
          
        
        
          What_WP are_VBP the_DT next_JJ steps_NNS in_IN management_NN at_IN this_DT time_NN ?_.
          Diabetes_NNP management_NN should_MD involve_VB a_DT multifaceted_JJ ,_, goal-directed_JJ approach_NN ,_, which_WDT
          includes_VBZ dietary_JJ modifications_NNS ,_, diabetes_NN education_NN ,_, assessment_NN of_IN blood_NN sugar_NN readings_NNS ,_,
          and_CC pharmacotherapy_NN ._. The_DT ADA_NNP recommends_VBZ glycemic_JJ and_CC other_JJ CVD_NNP risk_NN factor_NN goals_NNS (_( see_VB
          Table_NNP 2_LS )_) ,_, in_IN addition_NN to_TO foot_VB evaluation_NN and_CC screening_NN for_IN nephropathy_NN and_CC retinopathy_NN ,_,
          for_IN all_DT adults_NNS with_IN diabetes_NN [_NN 4_CD ]_NN ._. The_DT patient_NN is_VBZ started_VBN on_IN metformin_NN ,_, 500_CD mg_NN twice_RB daily_JJ
          (_( BID_NNP )_) with_IN meals_NNS ._. Therapy_NNP with_IN metformin_NN appears_VBZ to_TO decrease_VB the_DT risk_NN of_IN diabetes-related_JJ
          endpoints_NNS ,_, including_VBG a_DT reduction_NN in_IN cardiovascular_JJ events_NNS independent_JJ of_IN glycemic_JJ
          control_NN ._. There_EX is_VBZ also_RB less_JJR weight_NN gain_NN and_CC fewer_RBR hypoglycemic_JJ attacks_NNS than_IN with_IN insulin_NN
          and_CC sulphonylureas_NNS ._. Therefore_RB ,_, metformin_NN may_MD be_VB an_DT effective_JJ first-line_JJ pharmacotherapy_NN
          of_IN choice_NN in_IN these_DT patients_NNS [_NN 5_CD ]_NN ._. There_EX are_VBP several_JJ oral_JJ hypoglycemic_JJ agents_NNS (_( i_NNP ._. e_SYM ._. ,_,
          sulfonylureas_NNS ,_, metformin_NN ,_, acarbose_NN ,_, and_CC thiazolidinediones_NNS )_) that_WDT are_VBP effective_JJ
          monotherapy_NN for_IN reducing_VBG hyperglycemia_NN ._.
          The_DT patient_NN is_VBZ also_RB started_VBN on_IN low-dose_JJ aspirin_NN ,_, indicated_VBD for_IN primary_JJ prevention_NN of_IN
          macrovascular_NN disease_NN in_IN people_NNS with_IN diabetes_NN who_WP have_VBP any_DT risk_NN factors_NNS for_IN CVD_NNP [_NN 4_CD ]_NN ,_, and_CC
          a_DT cholesterol-lowering_JJ agent_NN ,_, a_DT statin_NN ,_, for_IN his_PRP$ increased_VBN LDL_NNP cholesterol_NN [_NN 6_CD ]_NN ._. He_PRP is_VBZ
          given_VBN a_DT glucose_NN meter_NN ,_, is_VBZ scheduled_VBN to_TO have_VB diabetes_NN education_NN classes_NNS and_CC diabetes_NN
          nutritional_JJ counseling_NN for_IN a_DT 1_CD ,_, 800_CD -_: calorie_NN ADA_NNP diet_NN ,_, and_CC is_VBZ instructed_VBN to_TO record_VB his_PRP$
          pre-meal_JJ blood_NN sugars_NNS ._. Smoking_NN cessation_NN is_VBZ another_DT important_JJ aspect_NN of_IN diabetes_NN
          management_NN to_TO address_VB ._. He_PRP returns_VBZ in_IN three_CD months_NNS for_IN follow-up_JJ and_CC has_VBZ an_DT HbA_NNP 1_CD c_SYM of_IN 7_CD ._. 3_CD %_NN ,_,
          at_IN which_WDT time_NN no_DT additional_JJ therapy_NN is_VBZ started_VBN ._.
        
        
          Three_CD Years_NNS Later_RB
          The_DT patient_NN is_VBZ now_RB 37_CD years_NNS old_JJ and_CC returns_NNS for_IN a_DT follow-up_JJ appointment_NN ._. He_PRP states_VBZ
          that_IN he_PRP has_VBZ felt_VBN “ pins_NNS and_CC needles_NNS” in_IN his_PRP$ feet_NNS and_CC fingertips_NNS ._. He_PRP has_VBZ had_VBN difficulty_NN
          with_IN maintaining_VBG erections_NNS but_CC has_VBZ a_DT normal_JJ libido_NN ._. Blood_NNP sugars_NNS are_VBP 160_CD –_NN 190_CD mg_NN /_NN dl_NN in_IN the_DT
          mornings_NNS and_CC 200_CD –_NN 240_CD mg_NN /_NN dl_NN in_IN the_DT evenings_NNS ,_, and_CC the_DT patient_NN reports_NNS no_DT hypoglycemic_JJ
          events_NNS ._. He_PRP has_VBZ diminished_VBN sensation_NN to_TO vibration_NN over_IN his_PRP$ right_NN great_JJ toe_NN and_CC left_VBD toes_NNS
          and_CC heel_NN with_IN intact_JJ monofilament_NN sensation_NN ._. The_DT remainder_NN of_IN his_PRP$ examination_NN is_VBZ
          unchanged_JJ ._. His_PRP$ medications_NNS are_VBP metformin_NN at_IN 1_CD g_SYM BID_NNP ,_, a_DT thiazide_NN diuretic_JJ at_IN 25_CD mg_NN QD_NNP ,_, a_DT
          statin_NN QD_NNP ,_, and_CC an_DT aspirin_NN QD_NNP ._. He_PRP is_VBZ 215_CD lb_NN ,_, BP_NNP is_VBZ 142_CD /_NN 86_CD mm_NN Hg_NNP ,_, and_CC pulse_NN is_VBZ 76_CD bpm_NN ._.
          Recent_JJ laboratory_NN tests_NNS produced_VBD the_DT following_JJ results_NNS :_: a_DT HbA_NNP 1_CD c_SYM of_IN 8_CD ._. 1_CD %_NN ,_, a_DT fasting_VBG
          glucose_NN of_IN 212_CD mg_NN /_NN dl_NN ,_, and_CC normal_JJ electrolytes_NNS ,_, creatinine_NN ,_, and_CC liver_NN enzymes_NNS ._. Fasting_NNP
          lipids_NNS are_VBP LDL_NNP 144_CD mg_NN /_NN dl_NN ,_, HDL_NNP 33_CD mg_NN /_NN dl_NN ,_, and_CC TG_NNP 209_CD mg_NN /_NN dl_NN ._.
          
            What_WP additional_JJ diagnostic_JJ tests_NNS would_MD be_VB helpful_JJ at_IN this_DT time_NN ,_, and_CC why_WRB ?_.
            A_DT spot_NN urine_NN albumin-to-creatinine_JJ ratio_NN is_VBZ 7_CD ._. 6_CD mg_NN /_NN mmol_NN ._. This_DT measurement_NN technique_NN
            is_VBZ preferred_VBN because_IN it_PRP has_VBZ lower_JJR rates_NNS of_IN false-positive_JJ and_CC false-negative_JJ results_NNS
            than_IN a_DT spot_NN urine_NN microalbumin_NN ._. Persistent_NNP microalbuminuria_NN should_MD be_VB confirmed_VBN on_IN two_CD
            or_CC three_CD subsequent_JJ readings_NNS within_IN a_DT six-month_JJ period_NN to_TO rule_VB out_IN false-positive_JJ
            results_NNS ._. The_DT elevated_VBD ratio_NN of_IN microalbumin_NN in_IN the_DT urine_NN signifies_NNS early_JJ nephropathy_NN
            because_IN microalbuminuria_NN has_VBZ been_VBN shown_VBN to_TO progress_VB to_TO macroalbuminuria_NN and_CC eventual_JJ
            nephropathy_NN in_IN type_NN 1_CD and_CC type_NN 2_CD diabetes_NN ._. Any_DT degree_NN of_IN albuminuria_NN is_VBZ a_DT risk_NN factor_NN
            for_IN cardiovascular_JJ events_NNS in_IN individuals_NNS with_IN or_CC without_IN diabetes_NN ;_: the_DT risk_NN increases_NNS
            with_IN the_DT level_NN of_IN absolute_JJ microalbuminuria_NN [_NN 7_CD ]_NN ._. Therefore_RB ,_, screening_NN for_IN
            microalbuminuria_NN should_MD be_VB done_VBN annually_RB in_IN all_DT people_NNS with_IN type_NN 1_CD and_CC type_NN 2_CD diabetes_NN
            [_NN 8_CD ]_NN ._.
            Annual_JJ screening_NN for_IN diabetic_JJ retinopathy_NN should_MD be_VB performed_VBN in_IN all_DT people_NNS with_IN
            diabetes_NN after_IN an_DT initial_JJ evaluation_NN and_CC reassessed_JJ more_RBR frequently_RB if_IN retinopathy_NN is_VBZ
            diagnosed_VBN ._. This_DT patient_NN remains_VBZ free_JJ of_IN retinopathy_NN ,_, but_CC a_DT significant_JJ number_NN of_IN
            patients_NNS with_IN type_NN 2_CD diabetes_NN have_VBP retinopathy_NN at_IN the_DT onset_NN of_IN diagnosis_NN owing_VBG to_TO the_DT
            insidious_JJ nature_NN of_IN type_NN 2_CD diabetes_NN and_CC the_DT failure_NN to_TO diagnose_NN type_NN 2_CD diabetes_NN early_JJ ._.
            Tight_NNP glycemic_JJ control_NN can_MD slow_VB the_DT progression_NN of_IN diabetic_JJ retinopathy_NN (_( Figures_NNS 1_CD –_NN 3_LS )_)
            [_NN 9_CD ]_NN and_CC help_VB prevent_VB development_NN of_IN proliferative_JJ diabetic_JJ retinopathy_NN ._.
          
          
            What_WP additional_JJ pharmacotherapy_NN should_MD be_VB started_VBN at_IN this_DT time_NN ?_.
            The_DT patient_NN has_VBZ developed_VBN neuropathy_NN and_CC erectile_NN dysfunction_NN ,_, both_DT of_IN which_WDT are_VBP
            complications_NNS of_IN diabetes_NN ._. He_PRP continues_VBZ to_TO have_VB suboptimal_NN glycemic_JJ control_NN ;_: therefore_RB ,_,
            additional_JJ therapy_NN in_IN the_DT form_NN of_IN combinations_NNS is_VBZ appropriate_JJ ._. The_DT patient_NN is_VBZ started_VBN
            on_IN a_DT thiazolidinedione_NN (_( TZD_NNP )_) QD_NNP ._. With_IN continued_VBD elevated_VBD systolic_JJ BP_NNP >_NN 130_CD mm_NN Hg_NNP and_CC
            diastolic_JJ BP_NNP >_NN 80_CD mm_NN Hg_NNP ,_, an_DT angiotensin-converting_JJ enzyme_NN inhibitor_NN (_( ACE-I_NNP )_) is_VBZ
            started_VBN ._. An_DT ACE-I_NNP at_IN this_DT time_NN is_VBZ appropriate_JJ for_IN BP_NNP control_NN and_CC has_VBZ the_DT additional_JJ
            preventative_JJ effects_NNS of_IN reducing_VBG progression_NN to_TO nephropathy_NN and_CC CVD_NNP events_NNS [_NN 10_CD ,_, 11_CD ]_NN ._. In_IN
            addition_NN ,_, continued_VBD strict_JJ BP_NNP control_NN is_VBZ as_RB effective_JJ as_IN tight_JJ glycemic_JJ control_NN in_IN
            preventing_VBG macrovasular_NN disease_NN in_IN diabetic_JJ patients_NNS and_CC slowing_VBG the_DT progression_NN of_IN
            diabetic_JJ nephropathy_NN and_CC retinopathy_NN [_NN 12_CD ]_NN ._. Erectile_NNP dysfunction_NN is_VBZ a_DT complication_NN
            associated_VBN with_IN diabetes_NN and_CC can_MD be_VB an_DT early_JJ sign_NN of_IN neuropathy_NN and_CC vascular_NN disease_NN ,_,
            therefore_RB a_DT phosphodiesterase-_NN 5_CD enzyme_NN inhibitor_NN is_VBZ an_DT appropriate_JJ choice_NN for_IN patients_NNS
            not_RB on_IN vasodilators_NNS or_CC with_IN a_DT history_NN of_IN significant_JJ CVD_NNP ._. The_DT statin_NN dose_NN is_VBZ increased_VBN
            to_TO achieve_VB a_DT goal_NN LDL_NNP of_IN ≤_NN 100_CD mg_NN /_NN dl_NN ._. Diabetic_NNP neuropathy_NN is_VBZ a_DT significant_JJ cause_NN of_IN
            morbidity_NN in_IN diabetes_NN ,_, and_CC its_PRP$ progression_NN correlates_NNS directly_RB with_IN glycemic_JJ control_NN ._.
            Tighter_NNP glucose_NN control_NN and_CC proper_JJ foot_NN care_NN are_VBP effective_JJ ._. It_PRP is_VBZ important_JJ to_TO continue_VB
            emphasis_NN on_IN dietary_JJ ,_, exercise_NN ,_, and_CC lifestyle_NN modifications_NNS in_IN addition_NN to_TO
            pharmacotherapy_NN ._.
          
        
        
          Five_CD Years_NNS Later_RB
          The_DT patient_NN returns_NNS to_TO clinic_NN today_NN after_IN spending_VBG the_DT last_JJ three_CD years_NNS overseas_JJ and_CC
          has_VBZ not_RB seen_VBN a_DT physician_NN in_IN two_CD years_NNS ._. He_PRP complains_VBZ of_IN fatigue_NN ,_, occasional_JJ blurry_JJ vision_NN ,_,
          awakening_VBG three_CD to_TO four_CD times_NNS at_IN night_NN to_TO urinate_NN ,_, and_CC diarrhea_NN at_IN least_JJS once_RB a_DT week_NN ._. He_PRP
          says_VBZ that_IN he_PRP has_VBZ been_VBN compliant_NN with_IN his_PRP$ diabetes_NN medications_NNS but_CC has_VBZ gained_VBN 15_CD lb_NN in_IN the_DT
          last_JJ six_CD months_NNS ._. His_PRP$ medications_NNS include_VBP metformin_NN at_IN 1_CD g_SYM BID_NNP ,_, a_DT TZD_NNP BID_NNP ,_, and_CC an_DT ACE-I_NNP
          QD_NNP ._. His_PRP$ blood_NN sugar_NN is_VBZ 289_CD mg_NN /_NN dl_NN (_( fasting_VBG )_) ,_, BP_NNP is_VBZ 130_CD /_NN 90_CD mm_NN Hg_NNP ,_, pulse_NN is_VBZ 88_CD bpm_NN ,_, and_CC
          weight_NN is_VBZ 221_CD lb_NN ._. There_EX are_VBP no_DT foot_NN sores_NNS or_CC ulcers_NNS ,_, but_CC he_PRP has_VBZ diminished_VBN sensation_NN to_TO
          monofilament_NN on_IN the_DT plantar_NN surfaces_VBZ of_IN both_DT feet_NNS ._. The_DT remainder_NN of_IN his_PRP$ examination_NN is_VBZ
          unchanged_JJ ,_, including_VBG normal_JJ fundoscopy_NN ._. His_PRP$ HbA_NNP 1_CD c_SYM is_VBZ 9_CD ._. 6_CD %_NN ,_, LDL_NNP is_VBZ 143_CD mg_NN /_NN dl_NN ,_, and_CC spot_NN
          urine_NN albumin-to-creatinine_JJ ratio_NN is_VBZ 15_CD mg_NN /_NN mmol_NN ._. His_PRP$ creatinine_NN and_CC liver_NN enzymes_NNS are_VBP
          normal_JJ ._. His_PRP$ pre-meal_JJ blood_NN sugars_NNS average_JJ 210_CD –_NN 250_CD mg_NN /_NN dl_NN ._.
          
            What_WP is_VBZ the_DT next_JJ most_RBS appropriate_JJ step_NN in_IN his_PRP$ medical_JJ management_NN ?_.
            He_PRP continues_VBZ to_TO have_VB an_DT elevated_VBD HbA_NNP 1_CD c_SYM ,_, worsening_VBG neuropathy_NN ,_, and_CC weight_NN gain_NN ,_, which_WDT
            prompt_VB a_DT more_RBR effective_JJ treatment_NN strategy_NN ._. There_EX are_VBP several_JJ options_NNS for_IN
            pharmacotherapy_NN available_JJ to_TO choose_VB from_IN at_IN this_DT point_NN ._. The_DT patient_NN could_MD begin_VB a_DT third_JJ
            oral_JJ agent_NN after_IN maximizing_VBG the_DT doses_NNS of_IN metformin_NN and_CC TZD_NNP ,_, or_CC he_PRP could_MD begin_VB insulin_NN
            injections_NNS with_IN or_CC without_IN additional_JJ oral_JJ agents_NNS ._. Because_IN of_IN the_DT significant_JJ cost_NN
            associated_VBN with_IN three_CD oral_JJ medications_NNS and_CC his_PRP$ need_NN for_IN further_JJ glycemic_JJ control_NN ,_,
            insulin_NN would_MD be_VB an_DT appropriate_JJ choice_NN at_IN this_DT time_NN ._. However_RB ,_, he_PRP should_MD be_VB advised_VBN of_IN
            the_DT side_NN effect_NN of_IN additional_JJ weight_NN gain_NN when_WRB beginning_VBG insulin_NN therapy_NN ._.
          
        
      
      
        DISCUSSION_NNP
        This_DT case_NN presentation_NN illustrates_VBZ an_DT otherwise_RB healthy_JJ appearing_VBG patient_NN who_WP is_VBZ found_VBN
        to_TO have_VB the_DT metabolic_JJ syndrome_NN and_CC despite_IN evidence-based_JJ management_NN develops_VBZ type_NN 2_CD
        diabetes_NN ._. This_DT patient_NN likely_JJ represents_VBZ the_DT natural_JJ history_NN of_IN type_NN 2_CD diabetes_NN in_IN most_JJS
        patients_NNS ._. Mild_NNP hypertension_NN is_VBZ often_RB the_DT only_RB presenting_VBG sign_NN of_IN metabolic_JJ syndrome_NN and_CC
        prediabetes_NNS ,_, allowing_VBG an_DT opportunity_NN for_IN prevention_NN of_IN type_NN 2_CD diabetes_NN ._.
        There_EX is_VBZ an_DT association_NN between_IN metabolic_JJ syndrome_NN and_CC the_DT development_NN of_IN CVD_NNP and_CC type_NN 2_CD
        diabetes_NN [_NN 13_CD ]_NN ._. This_DT syndrome_NN is_VBZ characterized_VBN not_RB only_RB by_IN the_DT criteria_NNS given_VBN in_IN Table_NNP 1_CD ,_,
        but_CC also_RB by_IN a_DT state_NN of_IN compensatory_JJ hyperinsulinemia_NN [_NN 14_CD ]_NN ._. However_RB ,_, a_DT diagnosis_NN of_IN
        metabolic_JJ syndrome_NN alone_RB does_VBZ not_RB imply_VB diabetes_NN ,_, as_IN patients_NNS with_IN metabolic_JJ syndrome_NN can_MD
        have_VB a_DT fasting_VBG plasma_NN glucose_NN less_JJR than_IN 110_CD mg_NN /_NN dl_NN ._. It_PRP is_VBZ the_DT body_NN 's_POS ability_NN to_TO maintain_VB
        glucose_NN utilization_NN and_CC suppress_VB endogenous_JJ glucose_NN production_NN in_IN the_DT setting_NN of_IN this_DT
        compensatory_JJ hyperinsulinemia_NN that_WDT separates_NNS metabolic_JJ syndrome_NN from_IN diabetes_NN ._. The_DT effect_NN
        of_IN this_DT hyperinsulinemic_JJ state_NN in_IN metabolic_JJ syndrome_NN is_VBZ also_RB believed_VBN to_TO be_VB involved_VBN in_IN
        excess_JJ pro-inflammatory_JJ and_CC pro-thrombotic_JJ markers_NNS associated_VBN with_IN the_DT development_NN of_IN
        diabetes_NN and_CC CVD_NNP [_NN 15_CD ]_NN ._. These_DT patients_NNS develop_VBP diabetes_NN when_WRB tissues_NNS of_IN the_DT body_NN fail_VB to_TO
        utilize_VB glucose_NN appropriately_RB owing_VBG to_TO increased_VB resistance_NN to_TO insulin_NN and_CC concomitant_NN
        beta-cell_JJ dysfunction_NN of_IN the_DT pancreas_NN [_NN 16_CD ]_NN ._.
        Metformin_NNP is_VBZ in_IN the_DT class_NN of_IN biguanides_NNS and_CC works_VBZ by_IN decreasing_VBG hepatic_JJ glucose_NN output_NN
        and_CC increasing_VBG insulin_NN action_NN in_IN tissues_NNS ._. Metformin_NNP has_VBZ been_VBN suggested_VBN to_TO help_VB prevent_VB the_DT
        onset_NN of_IN diabetes_NN but_CC is_VBZ less_RBR effective_JJ than_IN diet_NN and_CC lifestyle_NN changes_NNS [_NN 3_CD ]_NN ._. Other_JJ
        medications_NNS shown_VBN to_TO possibly_RB delay_VB or_CC prevent_VB the_DT onset_NN of_IN type_NN 2_CD diabetes_NN are_VBP ACE-I_NNP and_CC
        angiotensin_NN II_NNP receptor_NN blockers_NNS [_NN 17_CD ,_, 18_CD ]_NN ._. Patients_NNS treated_VBD with_IN diuretics_NNS can_MD progress_VB to_TO
        type_NN 2_CD diabetes_NN even_RB though_IN thiazide_NN diuretics_NNS are_VBP proven_VBN effective_JJ in_IN treating_VBG
        hypertension_NN [_NN 19_CD ,_, 20_CD ]_NN ._.
        Intensive_NNP therapy_NN in_IN patients_NNS with_IN type_NN 2_CD diabetes_NN results_NNS in_IN a_DT decreased_VBN risk_NN of_IN
        microvascular_NN complications_NNS ;_: therefore_RB ,_, it_PRP is_VBZ appropriate_JJ to_TO use_VB combinations_NNS of_IN
        medications_NNS in_IN patients_NNS with_IN suboptimal_NN glycemia_NN [_NN 21_CD ]_NN ._. The_DT class_NN of_IN TZDs_NNP works_VBZ to_TO lower_JJR
        plasma_NN glucose_NN levels_NNS by_IN increasing_VBG insulin_NN sensitivity_NN in_IN muscle_NN and_CC liver_NN [_NN 22_CD ]_NN ._. TZDs_NNP
        lower_JJR mean_NN HbA_NNP 1_CD c_SYM modestly_RB when_WRB added_VBD to_TO metformin_NN as_IN compared_VBN to_TO metformin_NN alone_RB [_NN 23_CD ]_NN ._. Side_NN
        effects_NNS include_VBP weight_NN gain_NN and_CC water_NN retention_NN ,_, and_CC patients_NNS with_IN a_DT history_NN of_IN New_NNP York_NNP
        Heart_NNP Association_NNP class_NN III_NNP or_CC IV_NNP heart_NN failure_NN should_MD not_RB use_VB TZDs_NNP [_NN 24_CD ,_, 25_CD ]_NN ._.
        The_DT pathophysiology_NN of_IN type_NN 2_CD diabetes_NN involves_VBZ ,_, in_IN part_NN ,_, a_DT “ relative_JJ” deficiency_NN of_IN
        insulin_NN ._. Although_IN a_DT state_NN of_IN endogenous_JJ hyperinsulinemia_NN occurs_VBZ ,_, the_DT degree_NN of_IN tissue_NN
        resistance_NN causes_VBZ a_DT total_JJ decrease_NN in_IN “ effective_JJ” endogenous_JJ insulin_NN ._. Progression_NNP of_IN
        disease_NN is_VBZ also_RB attributed_VBN to_TO worsening_VBG beta-cell_JJ dysfunction_NN and_CC decreased_VBD release_NN of_IN
        insulin_NN [_NN 26_CD ]_NN ._. Insulin_NNP is_VBZ used_VBN in_IN a_DT variety_NN of_IN combinations_NNS and_CC is_VBZ individualized_JJ to_TO patient_NN
        lifestyle_NN ._. A_DT frequent_JJ starting_NN dose_NN consists_VBZ of_IN a_DT long-_NN or_CC intermediate-acting_JJ insulin_NN ,_,
        such_JJ as_IN NPH_NNP insulin_NN ,_, divided_VBN into_IN morning_NN and_CC evening_NN doses_NNS ,_, or_CC insulin_NN glargine_NN given_VBN QD_NNP ,_,
        usually_RB at_IN bedtime_NN ._. The_DT patient_NN whose_WP$ case_NN is_VBZ described_VBN here_RB was_VBD started_VBN on_IN NPH_NNP at_IN bedtime_NN ,_,
        which_WDT decreases_VBZ overnight_JJ hepatic_JJ glucose_NN production_NN such_JJ that_IN the_DT patient_NN begins_VBZ the_DT
        morning_NN with_IN near-normal_JJ glycemia_NN for_IN daytime_JJ oral_JJ therapy_NN ._. There_EX may_MD be_VB times_NNS when_WRB a_DT
        post-meal_JJ surge_NN in_IN glucose_NN requires_VBZ extra_JJ insulin_NN in_IN addition_NN to_TO the_DT intermediate-acting_JJ
        NPH_NNP ._. In_IN such_JJ a_DT case_NN ,_, using_VBG a_DT short-acting_JJ (_( regular_JJ )_) insulin_NN before_IN meals_NNS provides_VBZ insulin_NN
        action_NN that_WDT closely_RB approximates_VBZ normal_JJ insulin_NN secretion_NN (_( Figure_NN 4_LS )_) ._. The_DT rapid-acting_JJ
        lispro_NN and_CC aspart_NN insulins_NNS have_VBP an_DT even_RB shorter_JJR half-life_NN and_CC quicker_JJR onset_NN of_IN action_NN than_IN
        regular_JJ insulin_NN ._. Common_NNP empirical_JJ initiation_NN doses_NNS range_VBP from_IN 0_CD ._. 4_CD –_NN 1_CD ._. 2_LS units_NNS of_IN insulin_NN per_IN
        kilogram_NN per_IN 24_CD hours_NNS ._. Patients_NNS should_MD be_VB advised_VBN of_IN hypoglycemia_NN and_CC weight_NN gain_NN as_IN the_DT
        main_JJ side_NN effects_NNS of_IN insulin_NN therapy_NN ._. Insulin_NNP and_CC insulin-sensitizer_JJ combinations_NNS
        significantly_RB improve_VBP hyperglycemia_NN ;_: however_RB ,_, there_EX is_VBZ an_DT increased_VBN incidence_NN of_IN heart_NN
        failure_NN reported_VBD with_IN this_DT combination_NN ,_, prompting_VBG close_NN monitoring_NN of_IN patients_NNS for_IN signs_NNS
        and_CC symptoms_NNS of_IN heart_NN failure_NN [_NN 27_CD ]_NN ._.
        In_IN summary_NN ,_, diabetes_NN prevention_NN and_CC management_NN is_VBZ an_DT important_JJ goal_NN in_IN practice_NN ._. The_DT
        morbidity_NN and_CC mortality_NN from_IN diabetes_NN is_VBZ a_DT significant_JJ burden_NN to_TO health_NN care_NN ,_, emphasizing_VBG
        the_DT need_NN for_IN effective_JJ prevention_NN and_CC control_NN of_IN diabetes_NN in_IN improving_VBG outcomes_NNS ._.
      
    
  
